Skip to main content
Daehan Nupharm Co.,Ltd. logo

Daehan Nupharm Co.,Ltd. — Investor Relations & Filings

Ticker · 054670 ISIN · KR7054670005 LEI · 988400PSHJB5UWD6MA19 KO Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 183 across all filing types
Latest filing 2026-05-19 Major Shareholding Noti…
Country KR South Korea
Listing KO 054670

About Daehan Nupharm Co.,Ltd.

https://www.dhnp.co.kr

Daehan Nupharm Co., Ltd. is a pharmaceutical company that develops, manufactures, and markets a wide range of health products. Its business is structured around four key segments: human pharmaceuticals, providing effective and safe therapeutics; animal health, offering products for both livestock and companion animals; biopharmaceuticals, focusing on the development of next-generation treatments such as cell therapy; and health functional foods. The company prioritizes innovation and quality through its dedicated research and development centers, aiming to advance health outcomes with scientifically-backed solutions.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 95% confidence The document is a Korean ‘주식등의 대량보유상황보고서’ (Large Shareholding Situation Report) filed under the Capital Markets Act, detailing the number of shares, ownership percentages, reporting dates, and related contractual arrangements. This is a notification of changes in significant share ownership levels. It does not contain financial results, director changes, or other report types. It therefore matches the Major Shareholding Notification category (MRQ).
2026-05-19 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 98% confidence The document is clearly titled “분기보고서” (Quaterly Report) for the 43rd fiscal period, covering 2026-01-01 to 2026-03-31 (first quarter). It contains full financial statements (summary financials, consolidated statements and notes), management discussion and analysis sections, detailed disclosures on business overview, capital changes, governance, auditor’s report, and other substantive financial data. This aligns with our definition for an Interim/Quarterly Report, not a brief announcement or certification. Therefore, it should be classified as IR (Interim / Quarterly Report). Q1 2026
2026-05-13 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 93% confidence The document is a Korean "주식등의 대량보유상황보고서(일반)" (Report on Large Shareholding Status) detailing the holdings and changes of a significant shareholder under capital markets law. It provides detailed share numbers, percentages, purposes of holding, contracts (e.g., stock collateral), and post-change holdings. This corresponds to a Major Shareholding Notification (MRQ) filing category.
2026-04-02 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 93% confidence The document is titled “정기주주총회 결과” and lists detailed voting outcomes for each agenda item at the Annual General Meeting, including approval status, vote percentages, and resolution details. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA) rather than presentation materials or other filings.
2026-03-27 Korean
감사보고서제출
Audit Report / Information Classification · 99% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) submitted to the Korea Exchange (KRX). It provides the audit opinion, key financial data, and confirmation of the audit process for the fiscal year ending 2025-12-31. While it contains financial data, it is a standalone regulatory disclosure regarding the audit report submission rather than the full Annual Report (10-K) or a simple announcement of report availability (RPA). Under the provided definitions, standalone audit reports and results of internal/regulatory audits fall under the 'AR' category. FY 2025
2026-03-18 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 98% confidence The document is a comprehensive financial report titled '재무제표에 대한 감사보고서' (Audit Report on Financial Statements) for Daehan New Pharm Co., Ltd. It includes the independent auditor's report, balance sheet, income statement, statement of changes in equity, cash flow statement, and detailed notes. While it contains an audit report, the document is a full set of audited financial statements for the fiscal year, which is the primary component of an Annual Report (10-K equivalent in the Korean regulatory context). FY 2025
2026-03-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.